Internal Medicine, Endocrinology, Diabetes, & Metabolism · Cape Coral, FL
NPI
1376808485
Since 2012
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
632 del Prado Blvd N Ste 1
Cape Coral, FL, 33909
Phone (239) 468-8076
Groups this clinician bills Medicare through
Medicare paid, 2024
$122K
2,858 services
Medicare patients, 2024
515
Average age 72
Drug cost, 2024
$1.5M
2,485 prescriptions
Company payments, 2025
$1,241
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Slavita M Laies was code J0897 (injection, denosumab, 1 mg), 1,501 times for 20 patients. In total Slavita M Laies billed 2,858 services in 20 codes, and Medicare paid $122K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-11-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,501 | 20 | $20.02 | $30K |
| 99214 Office E&M - Established | Office | 475 | 331 | $93.36 | $44K |
| 83036 Blood Count | Office | 166 | 147 | $9.41 | $1,561 |
| 99204 Office E&M - New | Office | 151 | 151 | $119.46 | $18K |
| 95251 Test - Miscellaneous | Office | 108 | 83 | $25.04 | $2,704 |
| 99205 Office E&M - New | Office | 73 | 73 | $160.53 | $12K |
| 99215 Office E&M - Established | Office | 63 | 56 | $136.26 | $8,585 |
| 99213 Office E&M - Established | Office | 41 | 41 | $59.21 | $2,428 |
| 96372 Injection Administration | Office | 26 | 20 | $9.68 | $252 |
| 82962 Clinical Chemistry | Office | 13 | 13 | $3.21 | $41.73 |
By year: 2022 $19K for 339 services; 2023 $118K for 2,227 services; 2024 $122K for 2,858 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 166 | 147 | $9.41 | $1,561 |
| 82962 Clinical Chemistry | 13 | 13 | $3.21 | $41.73 |
Medicare prescription drug claims, 2024
In 2024, the drug Slavita M Laies prescribed most often to Medicare patients was Ozempic (Semaglutide), with 253 prescriptions and refills. In total Slavita M Laies wrote 2,485 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 253 | 385 | 57 | $326K |
| Mounjaro Tirzepatide | 248 | 310 | 52 | $312K |
| Tresiba Flextouch U-100 Insulin Degludec | 193 | 503 | 60 | $97K |
| Levothyroxine Sodium Generic | 178 | 505 | 72 | $2,837 |
| Jardiance Empagliflozin | 125 | 299 | 43 | $161K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 118 | 240 | 41 | $9,424 |
| Synthroid Levothyroxine Sodium | 101 | 263 | 29 | $7,698 |
| Gvoke Hypopen 1-Pack Glucagon | 86 | 88 | 76 | $27K |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | 83 | 191 | 31 | $54K |
| Metformin Hcl Er Metformin Hcl | 76 | 160 | 28 | $814 |
| Rybelsus Semaglutide | 68 | 114 | 19 | $100K |
| Metformin Hcl Generic | 61 | 169 | 23 | $565 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 55 | 154 | 20 | $62K |
| Rosuvastatin Calcium Generic | 53 | 157 | 23 | $450 |
| Ezetimibe Generic | 48 | 139 | 20 | $1,204 |
Brand drugs: 1,614 claims; generic drugs: 663 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Slavita M Laies $1,241 ($1,241 in general payments such as food, travel and fees) from 15 companies. The largest payer was Novo Nordisk Inc with $282.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 7 | $282 |
| Abbott Laboratories ABT | 2 | $186 |
| Beta Bionics, Inc. BBNX | 4 | $170 |
| Amgen Inc. AMGN | 1 | $120 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $84.22 |
| Tandem Diabetes Care, Inc. TNDM | 2 | $79.39 |
| Medtronic, Inc. MDT | 2 | $66.03 |
| Dexcom, Inc. DXCM | 3 | $58.83 |
| Sequel Med Tech, LLC | 2 | $39.51 |
| Insulet Corporation PODD | 1 | $35.62 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.